



Índice numérico

Comunicações orais

- CO 1 PULMONARY ARTERY CATHETERIZATION IN CARDIOGENIC SHOCK - A PROPENSITY MATCHED ANALYSIS ON MANAGEMENT AND PROGNOSTIC IMPACT
- CO 2 LEFT VENTRICLE UNLOADING TECHNIQUES IN VA-ECMO: A COMPARATIVE ANALYSIS IN CARDIOGENIC SHOCK PATIENTS
- CO 3 VASODILATORY CARDIOGENIC SHOCK: EPIDEMIOLOGY, INVASIVE PHENOTYPING AND PROGNOSTIC IMPLICATIONS.
- CO 4 DECODING CARDIOGENIC SHOCK COMPLEXITY: VALIDATION AND PROGNOSTIC SIGNIFICANCE OF MACHINE-LEARNING PHENOTYPES IN A PORTUGUESE PATIENT COHORT
- CO 5 PREDICTORS OF ACUTE HEART TRANSPLANT REJECTION
- CO 6 SUBENDOCARDIAL “ISCHEMIC-LIKE” STATE IN PATIENTS WITH SEVERE AORTIC STENOSIS: INSIGHTS FROM MYOCARDIAL HISTOPATHOLOGY AND ULTRASTRUCTURE
- CO 7 SEX DIFFERENCES IN AORTIC STENOSIS PROGRESSION AND CARDIAC DAMAGE
- CO 8 LEFT VENTRICULAR DYSFUNCTION IN PATIENTS WITH AORTIC STENOSIS
- CO 9 TWO DECADES OF EFFECTIVE STENT IMPLANTATION IN AORTIC COARCTATION PATIENTS: A SINGLE-CENTER COHORT STUDY OF LONG-TERM HYPERTENSIVE BURDEN
- CO 10 AORTIC DP/DT AS A NEW TOOL FOR PREDICTION OF AORTIC STENOSIS PROGRESSION: A VALIDATION IN A SINGLE-CENTRE COHORT
- CO 11 TAVI FOR TREATING SEVERE AORTIC VALVE DISEASE IN CARDIOGENIC SHOCK - A SINGLE CENTRE EXPERIENCE
- CO 12 CLINICAL OUTCOMES OF NON-SEVERE PARAVALVULAR LEAK AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION.
- CO 13 TAVI VS BALLON AORTIC VALVULOPLASTY IN ACUTE DECOMPENSATED AORTIC STENOSIS
- CO 14 TIMING OF PCI IN TAVR PATIENTS IMPACT CLINICAL OUTCOMES
- CO 15 DIFFERENCES IN OUTCOMES BETWEEN PERCUTANEOUS CORONARY INTERVENTION OF CORONARY LESIONS AND MEDICAL THERAPY IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION
- CO 16 EFFECTIVENESS OF A CARDIAC REHABILITATION PROGRAM IN PATIENTS WITH HEART FAILURE AND SKELETAL MUSCLE WEAKNESS
- CO 17 MULTIMODAL NUTRITIONAL RISK SCREENING IN HEART FAILURE PATIENTS
- CO 18 WHAT IS THE TRUE NORMAL: COMPARISON OF DIFFERENT EQUATIONS FOR ESTIMATING PEAK OXYGEN UPTAKE FOR OUTCOME PREDICTION IN HEART FAILURE
- CO 19 EARLY OXYGEN PULSE PLATEAU AS A PROGNOSTIC MARKER IN A POPULATION OF PATIENTS WITH HEART FAILURE: HOW SOON IS TOO SOON?
- CO 20 CARDIAC REHABILITATION IN YOUNG PATIENTS POST ACUTE CORONARY SYNDROME: THE KEYSTONE IN CARDIOVASCULAR CARE
- CO 21 THE ROLE OF CARDIONEUROABLATION FOR THE TREATMENT OF HEART RHYTHM DISORDERS
- CO 22 AIMING-PACE: ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING-BASED PREDICTION MODEL FOR PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT

- CO 23 ELECTROCARDIOGRAPHIC IMAGING TO GUIDE ABLATION OF VENTRICULAR ARRHYTHMIAS SHOWS A HIGHER BENEFIT IN PATIENTS WITH LOW INTRAPROCEDURAL BURDEN
- CO 24 NEUROMODULATION IN ELECTRICAL STORM: SAFETY AND EFFICACY OF RENAL DENERVATION
- CO 25 CARDIONEUROABLATION USING EXTRACARDIAC VAGAL STIMULATION: A PROMISING ALTERNATIVE TO PACEMAKER THERAPY IN CARDIOINHIBITORY VASOVAGAL SYNCOPE
- CO 26 PROCEDURAL AND LONG-TERM PROGNOSIS AFTER SUCCESSFUL CTO RECANALIZATION IN PATIENTS WITH TYPE 2 DIABETES: A UNICENTRIC STUDY
- CO 27 ENHANCING PRIMARY PREVENTION: THE INCREMENTAL PREDICTIVE VALUE OF NTPROBNP BEYOND ASCVD RISK ASSESSMENT
- CO 28 ENHANCING PRIMARY PREVENTION: THE INCREMENTAL PREDICTIVE VALUE OF HSTNT BEYOND ASCVD RISK ASSESSMENT
- CO 29 CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY BEFORE INVASIVE CORONARY ANGIOGRAPHY IN CABG PATIENTS
- CO 30 INTEGRATING DIVERSE REAL WORLD DATA FOR ENHANCED PHENOTYPING OF CARDIOVASCULAR CHRONIC CONDITIONS
- CO 31 DOES THE LPA GENOTYPE HAVE A ROLE IN CORONARY ARTERY DISEASE RISK BEYOND LIPOPROTEIN(A) VALUES?
- CO 32 IS GENETIC INFORMATION HELPFUL IN PREDICTING RECURRENT EVENTS IN YOUNG PATIENTS AFTER ACUTE CORONARY SYNDROME?
- CO 33 GJA4 GENE INHIBITION MAY REPRESENT A POTENTIAL TARGET FOR NOVEL ANTITHROMBOTIC THERAPIES
- CO 34 THE EFFECT OF THE LPA GENE ON AORTIC VALVE CALCIFICATION IN A PORTUGUESE POPULATION
- CO 35 THE C825T GENETIC VARIANT OF THE G PROTEIN SS3 SUBUNIT IS ASSOCIATED WITH ESSENTIAL HYPERTENSION IN INDIVIDUALS WITH A FAMILY HISTORY OF ESSENTIAL HYPERTENSION
- CO 36 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS IN HEART FAILURE WITH REDUCED EJECTION FRACTION: EVALUATING EFFICACY IN THE ERA OF CONTEMPORARY PHARMACOTHERAPY
- CO 37 PROGNOSTIC IMPACT OF RESIDUAL CONGESTION ESTIMATED BY BIOIMPEDANCE IN HEART FAILURE
- CO 38 HEARTMATE 3™ EXPERIENCE: A SINGLE-CENTER RETROSPECTIVE STUDY
- CO 39 OPTIMAL TIMING OF CRT IMPLANTATION IN HEART FAILURE - A COMPARATIVE ANALYSIS OF LVEF RECOVERY AND DEVICE IMPLANTATION
- CO 40 HOME INTRAVENOUS DIURETICS: A WAY TO REDUCE HOSPITAL BED USAGE AND URGENT ADMISSIONS
- CO 41 PRE-TREATMENT WITH UNFRACTIONATED HEPARIN ALONGSIDE ASPIRIN AND A P2Y12 INHIBITOR IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
- CO 42 SEX DISPARITIES IN MID-TERM OUTCOMES OF ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION ACROSS AGE
- CO 43 CLINICAL VERSUS ALGORITHMIC PREDICTION OF OBSTRUCTIVE CORONARY ARTERY DISEASE - THE CASINO STUDY
- CO 44 OPTIMIZING COMPLETE REVASCULARIZATION STRATEGY IN STEMI: INSIGHTS FROM A REAL-WORLD SINGLE-CENTER ANALYSIS
- CO 45 CORONARY ARTERY ANEURISMS PRESENTING AS ACUTE CORONARY SYNDROME - ANTICOAGULATION THERAPY OR ANTIPLATELET THERAPY ALONE?
- CO 46 CLINICAL SIGNIFICANCE OF RIGHT VENTRICULAR PULMONARY ARTERIAL UNCOUPLING IN HYPERTROPHIC CARDIOMYOPATHY
- CO 47 CAN WE BETTER SELECT PATIENTS WITH CRYPTOGENIC STROKE FOR IMPLANTABLE LOOP RECORDERS? - THE IMPORTANCE OF ATRIAL STRAIN AS A PREDICTOR OF SUBCLINICAL ATRIAL FIBRILLATION
- CO 48 ASSESSING THE UTILITY OF THE INCREASED WALL THICKNESS SCORE IN DIAGNOSING ATTR CARDIOMYOPATHY - A VALIDATION STUDY
- CO 49 RADIOMIC FEATURES OF EPICARDIAL ADIPOSE TISSUE IN AF PROGRESSION
- CO 50 PREDICTORS OF LV REVERSE REMODELING AFTER SAVR: INSIGHTS FROM A PROSPECTIVE TTE AND CMR STUDY IN PATIENTS WITH SEVERE AORTIC STENOSIS.
- CO 51 SAFETY AND EFFECTIVENESS OF PULSED FIELD ABLATION FOR PULMONARY VEIN ISOLATION IN ATRIAL FIBRILLATION PATIENTS: A SINGLE CENTRE EXPERIENCE
- CO 52 PULSED FIELD ABLATION: A NEW ERA IN ATRIAL FIBRILLATION TREATMENT?
- CO 53 ANATOMIC-GUIDED ABLATION OF THE RIGHT GANGLIONATED PLEXI VALIDATED BY THE AUTOMATIC FRACTIONATION MAP
- CO 54 MINI-INVASIVE SURGICAL ABLATION AS AN ALTERNATIVE FOR TREATING ATRIAL FIBRILLATION RECURRENCE AFTER CATHETER ABLATION

- CO 55 CATHETER ABLATION FOR ATRIAL FIBRILLATION: UNVEILING KEY PREDICTORS OF LIFE QUALITY ENHANCEMENT
- CO 56 LONG-TERM EXERCISE TOLERANCE AND QUALITY OF LIFE AFTER BALLOON PULMONARY ANGIOPLASTY (BPA): IS THERE A ROLE FOR RIGHT HEART CATHETERIZATION?
- CO 57 UNMASKING EXERCISE PULMONARY HYPERTENSION - DOES TIME MATTER?
- CO 58 ENDARTERECTOMY IN CTEPH - HEMODYNAMIC IMPROVEMENT AND RV/PA COUPLING
- CO 59 WHITE SMOKE IN THE INTERMEDIATE RISK PE DEBATE - COULD POPE BE THE SOLUTION?
- CO 60 IDENTIFICATION OF A MULTI-ETIOLOGICAL SIGNATURE OF HEART FAILURE THROUGH MERGING OF MICROARRAY DATA
- CO 61 UNRAVELING THE COMPLEXITY OF HYPERTROPHIC CARDIOMYOPATHY: A MACHINE LEARNING-BASED RADIOMICS MODEL TO PREDICT PHENOTYPE AND CARDIOVASCULAR EVENTS
- CO 62 KASH SCORE - A CLINICAL SCORE TO PREDICT IN-HOSPITAL MORTALITY IN TAKOTSUBO SYNDROME
- CO 63 INVASIVE QUANTITATIVE ASSESSMENT OF CORONARY MICROVASCULAR DYSFUNCTION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- CO 64 LEFT VENTRICULAR TRANSRADIAL ENDOMYOCARDIAL BIOPSY IN VAL30MET PATIENTS AND NEGATIVE BONE SCINTIGRAPHY: CHANGING DIAGNOSTIC PARADIGM
- CO 65 REFINING THE DIAGNOSIS OF HYPERTROPHIC CARDIOMYOPATHY WITH A MACHINE LEARNING-BASED RADIOMICS MODEL: A CARDIOVASCULAR MAGNETIC RESONANCE STUDY
- CO 66 CARDIOGENIC SHOCK MANAGEMENT WITH VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION: A SINGLE-CENTER ANALYSIS
- CO 67 INTRA-AORTIC BALLOON PUMP PLACEMENT AT THE BEDSIDE: A SINGLE-CENTER EXPERIENCE OF CICU VERSUS CATHLAB INSERTION, MANAGEMENT, AND REMOVAL.
- CO 68 DIASTOLIC SHOCK INDEX: A NOVEL PROGNOSTIC PARAMETER UNVEILING INSIGHTS INTO VASODILATORY CARDIOGENIC SHOCK
- CO 69 VENOARTERIAL EXTRACORPOREAL MEMBRANE OXIGENATION FOR INFARCT RELATED CARDIOGENIC SHOCK: A REAL-WORLD COMPARISON OF PATIENT CANDIDATES, PRACTICES AND OUTCOMES
- CO 70 EVALUATING THE OUTCOMES OF BEDSIDE PERCUTANEOUS PERIPHERAL VA-ECMO DECANNULATION USING A PERCLOSE PROGLIDE SUTURE-MEDIATED POST-CLOSURE PROCEDURE IN A HIGH-VOLUME ECMO CENTRE
- CO 71 LIPOPROTEIN (A) AS A RISK MARKER FOR WORSE OUTCOMES IN ACUTE MYOCARDIAL INFARCTION PATIENTS
- CO 72 ACUTE CORONARY SYNDROMES: DISPARITIES IN THE INITIAL APPROACH FOR MEN AND WOMEN
- CO 73 GENDER DISPARITIES IN ACUTE CORONARY SYNDROMES: A COMPREHENSIVE ANALYSIS OF MANAGEMENT, TREATMENT, AND PROGNOSIS
- CO 74 EVALUATING ECONOMIC IMPACT OF GENERIC PRASUGREL WIDESPREAD ADOPTION
- CO 75 DAPAGLIFLOZIN'S INFLUENCE ON CARDIAC REMODELING IN CHRONIC HEART FAILURE PATIENTS
- CO 76 LEFT BUNDLE BRANCH AREA PACING: THE INITIAL EXPERIENCE AT A PORTUGUESE TERTIARY CENTER
- CO 77 FROM RIGHT TO LEFT: LEFT BUNDLE BRANCH AREA PACING VS CONVENTIONAL RIGHT VENTRICULAR PACING
- CO 78 LEADLESS PACING SYSTEM: REAL-WORD COMPARISON BETWEEN TWO SYSTEM DEVICES
- CO 79 META-ANALYSIS COMPARING CARDIAC RESYNCHRONIZATION THERAPY WITH OR WITHOUT DEFIBRILLATION IN PATIENTS WITH NON-ISCHEMIC CARDIOMYOPATHY
- CO 80 INITIAL EXPERIENCE AND MEDIUM-TERM RESULTS OF LEFT BUNDLE BRANCH AREA PACING
- CO 81 TRICUSPID TRANSCATHETER EDGE-TO-EDGE REPAIR (TEER): RIGHT VENTRICLE (RV) FUNCTION AND RV-PULMONARY ARTERY (RV-PA) COUPLING CHARACTERIZATION IN A REAL-WORLD SETTING
- CO 82 LEFT ATRIAL STIFFNESS AS A PREDICTOR OF SUBCLINICAL ATRIAL FIBRILLATION AND A MARKER OF STROKE RECURRENCE IN A COHORT OF PATIENTS WITH CRYPTOGENIC STROKE
- CO 83 UROCORTIN-2 AS A NOVEL BIOMARKER OF CLINICAL DETERIORATION IN HFPEF: A PROSPECTIVE COHORT STUDY
- CO 84 CAPL-SCORE: ANTICIPATING FUTILITY IN TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)
- CO 85 LEFT ATRIAL WALL THICKNESS MEASURED BY A MACHINE LEARNING METHOD PREDICTS AF RECURRENCE AFTER PULMONARY VEIN ISOLATION
- CO 86 MACHINE-LEARNING BASED RADIOMICS MODEL TO PREDICT VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- CO 87 RIGHT VENTRICULAR MYOCARDIAL WORK: PROOF-OF-CONCEPT FOR NON-INVASIVE ASSESSMENT OF RIGHT VENTRICULAR FUNCTION IN PULMONARY HYPERTENSION PATIENTS.

- CO 88 REVISITING RISK STRATIFICATION IN HYPERTROPHIC CARDIOMYOPATHY AFTER RECENT GUIDELINES - LATE GADOLINIUM ENHANCEMENT REMAINS TOUGH TO BEAT
- CO 89 TAFAMIDIS FOR THE TREATMENT OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS (ATTR-CM) - REAL-WORLD DATA FROM A TERTIARY CENTER
- CO 90 THE USE OF LATE GADOLINIUM ENHANCEMENT TO IMPROVE THE YIELD OF GENETIC TESTING IN DILATED CARDIOMYOPATHY
- CO 91 TECHNIQUE OF MINISTERNOTOMY IN AORTIC VALVE REPLACEMENT. DOES INTRAOPERATIVE CONVERSION TO FULL STERNOTOMY INCREASE MORBIDITY AND MORTALITY? A SINGLE CENTER ANALYSIS.
- CO 92 SURGICAL AORTIC VALVE REPLACEMENT FOLLOWING DECLINED TRANSCATHETER AORTIC VALVE IMPLANTATION
- CO 93 LONG-TERM OUTCOME OF ACUTE TYPE A AORTIC DISSECTIONS: A 20-YEAR SINGLE-CENTER CASUISTIC
- CO 94 LEAD EXTRACTIONS IN A SINGLE CENTER: A RECTROSPECTIVE ANALYSIS OVER THE LAST 26 YEARS
- CO 95 CORONARY ATHEROSCLEROTIC BURDEN IN MASTER ATHLETES: RELATIONSHIP WITH CARDIOVASCULAR RISK AND VOLUME OF EXERCISE
- CO 96 NON-INVASIVE DERIVATION OF IFR FROM INVASIVE CORONARY ANGIOGRAPHY USING A NEW DEEP LEARNING AI MODEL AND COMPARISON WITH HUMAN OPERATORS' PERFORMANCE
- CO 97 LONG TERM PROGNOSIS OF IDIOPATHIC VENTRICULAR ARRHYTHMIAS: AN EIGHTEEN-YEAR EXPERIENCE FROM A TERTIARY CENTER
- CO 98 COMPUTED TOMOGRAPHY-DERIVED MYOCARDIAL EXTRACELLULAR VOLUME AS A PROGNOSIS PREDICTOR IN PATIENTS WITH SEVERE AORTIC STENOSIS
- CO 99 LONG-TERM OUTCOMES OF VENTRICULAR TACHYCARDIA ABLATION IN PATIENTS WITH ISCHEMIC AND NON-ISCHEMIC CARDIOMYOPATHY: A PROPENSITY-SCORE MATCHED ANALYSIS

Posters

- PO 1 LEFT ATRIAL APPENDAGE CLOSURE: DOES SHAPE MATTER?
- PO 2 BALLOON PULMONARY ANGIOPLASTY FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: SAFETY AND PROCEDURAL TOLERANCE IN ELDERLY PATIENTS
- PO 3 SAME-DAY DISCHARGE AFTER ELECTIVE PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE
- PO 4 CAROTID ARTERY STENTING: A DESCRIPTIVE ANALYSIS OF A TERTIARY HOSPITAL'S EXPERIENCE
- PO 5 LEFT VENTRICULAR TRANSRADIAL ENDOMYOCARDIAL BIOPSY: A SAFE AND EFFECTIVE APPROACH
- PO 6 CORONARY SINUS REDUCER DEVICE FOR THE TREATMENT OF REFRACTORY ANGINA. A SINGLE CENTRE EXPERIENCE
- PO 7 PERFORM SCORE: A PROGNOSTIC TOOL FOR PREDICTING NEED FOR FIBRINOLYSIS IN PULMONARY EMBOLISM
- PO 8 SERUM ALKALINE PHOSPHATASE AS A RISK-STRATIFICATION TOOL IN PULMONARY EMBOLISM
- PO 9 RESIDUAL PULMONARY HYPERTENSION AFTER PEA - AN ILL-DEFINED PROBLEM
- PO 10 BALLOON PULMONARY ANGIOPLASTY IN CTEPH - READY FOR THE FRONTLINE?
- PO 11 PREVALENCE AND PREDICTORS OF NORMOTENSIVE CARDIOGENIC SHOCK IN INTERMEDIATE-HIGH RISK PULMONARY EMBOLISM
- PO 12 POOR PROGNOSIS IN PATIENTS WITH ACUTE PULMONARY EMBOLISM TREATED WITH MECHANICAL THROMBECTOMY
- PO 13 LEFT ATRIAL VOLUME PREDICTS MAJOR ADVERSE CARDIAC EVENTS AFTER CATHETER ABLATION FOR ATRIAL FIBRILLATION
- PO 14 IMPLANTABLE LOOP RECORDER MONITORING IN CARDIOMYOPATHIES: UNVEILING CLINICALLY RELEVANT ARRHYTHMIAS
- PO 15 IMPROVING ADHERENCE TO ANTICOAGULATION: A NUDGE STRATEGY-BASED INTERVENTION ON PATIENTS WITH ATRIAL FIBRILLATION OR ATRIAL FLUTTER SCHEDULED FOR ELECTRICAL CARDIOVERSION
- PO 16 DIAGNOSTIC YIELD OF 24-HOUR HOLTER MONITORING IN NONAGENARIANS - INSIGHTS FROM A SINGLE-CENTER COHORT
- PO 17 LEFT ATRIAL APPENDAGE CLOSURE (LAA): A COMPREHENSIVE ANALYSIS OF PERIPROCEDURAL AND LONG-TERM OUTCOMES IN ELDERLY PATIENTS.
- PO 18 BEYOND 55: CLINICAL PERSPECTIVES ON TRANSCATHETER PFO CLOSURE - INSIGHTS FROM A UNICENTER STUDY
- PO 19 UNVEILING MORTALITY OUTCOMES IN CARDIOGENIC SHOCK ADULT PATIENTS WITH PERIPHERAL VENOARTERIAL EXTRACORPOREAL MEMBRANE OXIGENATION

- PO 20 IABP IMPLANTATION TRENDS AFTER THE TRIALS - WHEN IT GETS CRITICAL, DO WE FOLLOW GUIDELINES?
- PO 21 REAL-WORLD INSIGHTS: PRACTICAL IMPELLA OUTCOMES IN CARDIOGENIC SHOCK AND HIGH-RISK ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
- PO 22 VASCULAR COMPLICATIONS OF INTRA-AORTIC BALLOON PUMP (IABP) IMPLANTATION - A SINGLE-CENTER ANALYSIS.
- PO 23 CARDIOGENIC SHOCK FOLLOWING ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN WOMEN: COMPLICATIONS AND OUTCOMES.
- PO 24 CALCIUM HIDES THE CLUE: UNRAVELING THE DIAGNOSTIC VALUE OF EARLY CORONARY CALCIUM SCORING IN CARDIAC ARREST SURVIVORS
- PO 25 OUT-OF-HOSPITAL CARDIAC ARREST: EPIDEMIOLOGY, ICU OUTCOMES, AND PROGNOSTIC INSIGHTS
- PO 26 BEYOND THE ARREST: ASSESSING SURVIVAL WITH SOFA AND SAPS II SCORES IN OHCA PATIENTS
- PO 27 SURVIVAL CLOCK: UNVEILING MORTALITY PREDICTORS IN OUT-OF-HOSPITAL CARDIAC ARREST
- PO 28 ANALYZING THE RVOT ENVELOPE IN PULMONARY HYPERTENSION - SIMPLICITY IS KEY
- PO 29 AI AUTOMATED ECHOCARDIOGRAPHIC MEASUREMENTS - IS THIS THE FUTURE?
- PO 30 THREE-DIMENSIONAL ECHOCARDIOGRAPHY FOR THE ASSESSMENT OF RIGHT VENTRICULO-ARTERIAL COUPLING IN PRE-CAPILLARY PULMONARY HYPERTENSION.
- PO 31 NONINVASIVE MEASUREMENT OF MEAN PULMONARY ARTERY PRESSURE THROUGH ECHOCARDIOGRAPHY - IS IT A RELIABLE ALTERNATIVE?
- PO 32 THE FLUTTER-BY EFFECT IN TRANSCATHETER AORTIC VALVE IMPLANTATION BIOPROSTHESIS
- PO 33 PERFORMANCE OF THREE DIMENSIONAL RIGHT VENTRICULAR EVALUATION AND RIGHT VENTRICULAR STRAIN IN SICKLE CELL DISEASE PATIENTS
- PO 34 ECHOCARDIOGRAPHY IN PULMONARY HYPERTENSION HEMODYNAMIC EVALUATION - A SILVER LINING
- PO 35 MYOCARDIAL WORK IN ATHLETES: A NOVEL APPROACH TO DIFFERENTIATE ATHLETIC HEART ADAPTATIONS FROM CARDIOMYOPATHY?
- PO 36 ASSESSING THE VALUE OF ROUTINE CONTRAST ECHOCARDIOGRAPHY FOR LEFT VENTRICULAR THROMBUS SCREENING IN ANTERIOR ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS
- PO 37 THE UNUSUAL SUSPECT - IS PULMONARY VENO-OCCLUSIVE DISEASE UNDERRECOGNIZED?
- PO 38 ECHOCARDIOGRAPHIC INSIGHTS REDEFINING RISK IN PULMONARY ARTERIAL HYPERTENSION: A FOCUS ON RIGHT ATRIAL VOLUME INDEX FOR ENHANCED STRATIFICATION
- PO 39 FOUR-STRATA RISK-ASSESSMENT TOOL FOR PULMONARY HYPERTENSION: CAN WE ASSOCIATE IT WITH HAEMODYNAMIC PARAMETERS?
- PO 40 ASSESSING INVASIVE HEMODYNAMICS IN PULMONARY HYPERTENSION: EXAMINING THE PREDICTIVE UTILITY OF CARBOHYDRATE ANTIGEN 125 AND N-TERMINAL PRO-BRAIN-TYPE NATRIURETIC PEPTIDE
- PO 41 GENETIC TESTING IN PAH: ASSESSING CLINICAL RISK AND PROGNOSTIC SIGNIFICANCE OF MUTATIONS
- PO 42 ESTUDO SHAPE - UMA PRIMEIRA FOTOGRAFIA À REALIDADE DA HIPERTENSÃO ARTERIAL PULMONAR EM PORTUGAL
- PO 43 CONNECTIVE TISSUE DISEASE AND PULMONARY HYPERTENSION - AN OMINOUS ASSOCIATION
- PO 44 FOUR STRATA RISK STRATIFICATION IN PULMONARY ARTERIAL HYPERTENSION: IS IT REALLY ENOUGH?
- PO 45 ASSESSING THE ARTERIAL-VENTRICULAR UNCOUPLING IN PULMONARY ARTERIAL HYPERTENSION - IS THERE A PLACE FOR STROKE VOLUME INDEX?
- PO 46 REAMING AT RESISTANT HYPERTENSION: OLD WEAPONS BROUGHT BACK.
- PO 47 SIGNIFICANCE OF NOCTURNAL DIASTOLIC BLOOD PRESSURE IN PREDICTING OUTCOMES IN HYPERTENSIVE DISORDERS OF PREGNANCY
- PO 48 AMBULATORY PULSE PRESSURE MONITORING AS A PROGNOSTIC INDICATOR FOR CARDIOVASCULAR EVENTS IN A HYPERTENSIVE POPULATION
- PO 49 UNRAVELING THE STRUCTURAL AND FUNCTIONAL ADAPTATIONS IN HYPERTENSIVE HEART DISEASE: WHAT LIES BEYOND LEFT VENTRICULAR HYPERTROPHY?
- PO 50 LONG-TERM OUTCOMES AFTER RENAL DENERVATION: A FOLLOW-UP OF 5 YEARS
- PO 51 BASELINE RENIN LEVELS AND THE EFFICACY OF MINERALOCORTICOID INHIBITORS: A META-ANALYSIS
- PO 52 TRANSCATHETER AORTIC VALVE REPLACEMENT AND BICUSPID AORTIC VALVE
- PO 53 SURVIVAL IN VERY ELDERLY PATIENTS SUBMITTED TO TAVI COMPARED TO THE GENERAL POPULATION

- PO 54 OUTCOMES OF INFECTIVE ENDOCARDITIS AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION VERSUS AORTIC VALVE REPLACEMENT SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 55 30-DAY AND 1-YEAR MORTALITY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: THE IMPACT OF BALLOON AORTIC VALVULOPLASTY AS A BRIDGING THERAPY IN A TERTIARY CENTER
- PO 56 CONTRACTILE RESERVE AND SURVIVAL OUTCOMES IN TRANSCATHETER AORTIC VALVE IMPLANTATION FOR LOW-FLOW, LOW-GRADIENT AORTIC STENOSIS
- PO 57 ORAL ANTICOAGULATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 58 SMALL CHANGES CAN MAKE A DIFFERENCE: THE IMPACT OF DIFFERENT AJMALINE CHALLENGE PROTOCOLS ON CARBON FOOTPRINT
- PO 59 ATIVIDADE CIENTÍFICA E SATISFAÇÃO GLOBAL NO INTERNATO MÉDICO - A REALIDADE OUTLIER DA CARDIOLOGIA
- PO 60 TRENDS AND INSIGHTS INTO CONGENITAL HEART DISEASE EPIDEMIOLOGY IN PORTUGAL: A TWO-DECADE PERSPECTIVE
- PO 61 A GLOBAL PERSPECTIVE ON LIPID CONTROL AFTER ACUTE CORONARY SYNDROME - ARE WE DOING ENOUGH?
- PO 62 ANÁLISE DA PERSPETIVA DOS JOVENS CARDIOLOGISTAS SOBRE AS ATUAIS MATRIZES DO INTERNATO EM PORTUGAL - RESULTADOS PRELIMINARES
- PO 63 REAL-LIFE IMPACT OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS AFTER ACUTE CORONARY SYNDROME
- PO 64 IS THE TRIGLYCERIDE GLUCOSE INDEX A VALUABLE MARKER IN THE EARLY IDENTIFICATION OF CARDIOVASCULAR EVENTS?
- PO 65 LIPOPROTEIN(A) ROLE IN ACUTE MYOCARDIAL INFARCTION: REAL-WORLD DATA OF A TERTIARY CARE CENTRE
- PO 66 TARGET LIPID GOALS IN VERY HIGH RISK CARDIOVASCULAR PATIENTS - RESULTS FROM A SECONDARY PREVENTION OUTPATIENT PROGRAM
- PO 67 DO TRIGLYCERIDES IMPACT CARDIOVASCULAR OUTCOMES? A 10-YEAR FOLLOW UP STUDY FROM A PORTUGUESE COHORT
- PO 68 EFFICACY OF ORAL HYPOLIPIDEMIC THERAPIES IN A REAL WORLD POPULATION
- PO 69 DIABETES MELLITUS INFLUENCE IN LIPOPROTEIN(A) GENE EXPRESSION AND ASSOCIATION TO CORONARY ARTERY DISEASE
- PO 70 CAN SYSTEMIC IMMUNE INFLAMMATORY INDEX BEAT 18F-FDG PET-CT IN IDENTIFYING BREAST CANCER PATIENTS WITH INCREASED RISK OF VASCULAR DISEASE?
- PO 71 RISK OF ADVERSE CARDIOVASCULAR EVENTS ACROSS THE GLOBAL LONGITUDINAL STRAIN SPECTRUM IN RHEUMATOID ARTHRITIS PATIENTS
- PO 72 ASSESSING MYOCARDIAL RECOVERY AND VENTRICULAR REMODELING AFTER ACUTE MYOCARDITIS
- PO 73 DO CARDIAC BIOMARKERS PREDICT SHORT AND LONG-OUTCOMES IN ACUTE MYOCARDITIS? RESULTS OF A LONG-TERM PROSPECTIVE STUDY
- PO 74 SAMY SCORE: A DISCRIMINATIVE TOOL FOR DISTINGUISHING MYOCARDITIS FROM ACUTE CORONARY SYNDROME
- PO 75 WHAT IS THE LONG-TERM PROGNOSIS OF ACUTE MYOCARDITIS? RESULTS OF A LONG-TERM PROSPECTIVE STUDY
- PO 76 CANCER THERAPY-RELATED CARDIOVASCULAR TOXICITY: WHAT'S THE ACCURACY OF BASELINE CARDIOVASCULAR RISK STRATIFICATION IN THE PREDICTION OF ITS OCCURRENCE?
- PO 77 CHARACTERIZATION OF LEFT ATRIAL FUNCTION DURING CARDIAC REMODELING AND REVERSE REMODELING INDUCED BY PREGNANCY
- PO 78 IMPACT OF CARDIOVASCULAR RISK FACTORS IN CARDIAC REMODELLING AND REVERSE REMODELLING INDUCED BY PREGNANCY
- PO 79 ARE STATINS PREVENTIVE OF CARDIOTOXICITY IN BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINES? A SINGLE CENTER RETROSPECTIVE ANALYSIS
- PO 80 MORBIDITY AND MORTALITY OF CARDIO-ONCOLOGY PATIENTS: IS THERE ANY LINK TO BASELINE CARDIOVASCULAR RISK?
- PO 81 18F-FDG UPTAKE AS A SURROGATE MARKER OF VASCULAR DISEASE IN BREAST CANCER: THE ROLE OF ROUTINE EXAMS IN CARDIOVASCULAR RISK EVALUATION
- PO 82 SAME-DAY DISCHARGE AFTER ATRIAL FIBRILLATION ABLATION: IS IT SAFE?
- PO 83 PULMONARY VEINS ANATOMY VARIANTS AND CRYOBALLOON ABLATION FOR ATRIAL FIBRILLATION
- PO 84 EARLY EXPERIENCE WITH A NEW MULTI-ELECTRODE RADIOFREQUENCY BALLOON USING INTEGRATED 3D IMAGING FOR PULMONARY VEIN ISOLATION IN ATRIAL FIBRILLATION

- PO 85 CHARACTERIZING RECURRENT ATRIAL FIBRILLATION AFTER CATHETER ABLATION: PATTERNS OF PULMONARY VEIN RECONNECTION AND PREDICTORS OF COMPLETE PULMONARY VEIN ISOLATION
- PO 86 ROLE OF COMBINED PULMONARY VEIN ISOLATION WITH LEFT ATRIAL GANGLIONATED PLEXUS ABLATION IN PAROXYSMAL ATRIAL FIBRILLATION AND SINUS BRADYCARDIA
- PO 87 ECHOCARDIOGRAPHIC FACTORS IN SHORT TERM RECURRENCE AFTER ATRIAL FIBRILLATION ABLATION
- PO 88 SGLT2 INHIBITORS IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: WHAT TO EXPECT?
- PO 89 CHARACTERIZATION OF PATIENTS WITH CARDIAC AMYLOIDOSIS DIAGNOSED AT THE TIME OF IDIOPATHIC CARPAL TUNNEL SURGERY
- PO 90 THERAPEUTIC VALUE OF SPIRONOLACTONE IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
- PO 91 12-MONTH EFFECT OF TAFAMIDIS ON THE CLINICAL PROGRESSION OF CARDIAC AMYLOIDOSIS IN A SINGLE CENTRE COHORT
- PO 92 TRANSCATHETER AORTIC VALVE REPLACEMENT IN PATIENTS WITH COEXISTENT CARDIAC AMYLOIDOSIS
- PO 93 SGLT2I ON TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: A NEW DRUG FOR AN UNDER-RECOGNIZED CARDIOMYOPATHY
- PO 94 DOES FRAILITY HAVE AN INFLUENCE ON MINOCA?
- PO 95 PACEMAKER IMPLANTATION IN THE ELDERLY: CAN THE PATIENT'S LEVEL OF DEPENDENCE SELECT THE BEST CANDIDATES FOR DEVICE IMPLANTATION?
- PO 96 PHASE ANALYSIS OF SINGLE-PHOTON EMISSION COMPUTERIZED TOMOGRAPHY MYOCARDIAL PERFUSION IMAGING (SPECT-MPI): CLOSER TO THE ROOT OF LEFT BUNDLE BRANCH BLOCK CARDIOMYOPATHY?
- PO 97 FLUID OVERLOAD AT THE BEGINNING OF PERITONEAL DIALYSIS AND ITS ASSOCIATION WITH SERUM NT-PROBNP AND CA-125
- PO 98 ACUTE AORTIC SYNDROMES IN A CENTER WITHOUT ON-SITE CARDIAC SURGERY
- PO 99 ACUTE STANFORD TYPE A AORTIC DISSECTIONS - THE EXPERIENCE OF AN ULTRA-PERIPHERAL CENTER
- PO 100 24H-HOLTER MONITORING IN MYOTONIC DYSTROPHY TYPE 1 FOLLOW-UP: IS IT REALLY NEEDED?
- PO 101 CYBERNETIC GUARDIANS: REVOLUTIONIZING CARDIAC CARE THROUGH REMOTE MONITORING OF IMPLANTABLE DEVICES
- PO 102 PROGNOSTIC IMPACT OF MAXIMAL NOCTURNAL HEART RATE IN HEART FAILURE PATIENTS WITH AN IMPLANTABLE ELECTRONIC DEVICE.
- PO 103 PROLONGED ANTIBIOTIC THERAPY BEFORE LEAD EXTRACTION IN CARDIAC IMPLANTABLE ELECTRONIC DEVICE INFECTIONS AS A WAY FOR DIMINISHING THE RATE OF SEPTIC SHOCK.
- PO 104 INCIDENTAL NON-INFECTIOUS MASSES ON CARDIAC IMPLANTABLE ELECTRONIC DEVICE LEADS
- PO 105 EARLY DISCHARGE FOLLOWING CARDIAC IMPLANTABLE ELECTRONIC DEVICE IMPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 106 OUTCOMES OF FAMILY SCREENING FOR HEREDITARY CARDIAC DISEASES SCREENING - GENETIC CONFIRMED CARDIOMYOPATHY OR ARRHYTHMIA AS MODELS FOR PRIMARY PREVENTION
- PO 107 DIFFERENT VARIANTS, SAME GENE: SIMILAR OR DIFFERENT EVOLUTIONARY BEHAVIOR THROUGHOUT LIFE?
- PO 108 INTERPRETING GENETIC TESTING FOR INHERITED CARDIAC DISORDERS
- PO 109 CARDIAC INVOLVEMENT AFTER LIVER TRANSPLANTATION IN FAMILIAL AMYLOID POLYNEUROPATHY - A CONTINUING CHALLENGE
- PO 110 RASOPATHIES - CARDIAC MANIFESTATIONS AND OUTCOMES IN A TERTIARY CENTER COHORT STUDY
- PO 111 UPTAKE OF GENETIC COUNSELLING AND GENETIC TESTING IN INHERITED CARDIOMYOPATHIES AND ARRHYTHMIAS IN A PORTUGUESE REFERENCE GENETIC DEPARTMENT
- PO 112 HEART FAILURE AND CHRONIC KIDNEY DISEASE: CHLORIDE AND MARKERS OF FLUID OVERLOAD AND DIURETIC RESISTANCE
- PO 113 NT-PROBNP IS NOT A GOOD PROGNOSTIC MARKER IN PATIENTS WITH ADVANCED HEART FAILURE ON AMBULATORY LEVOSIMENDAN INFUSION PROGRAM
- PO 114 PHENOTYPING HEART FAILURE PATIENTS WITH SUBCLINICAL CONGESTION
- PO 115 PREDICTING HEART FAILURE OUTCOMES WITH A NEW MALNUTRITION AND INFLAMMATION SEVERITY INDEX - MISI SCORE
- PO 116 PREDICTORS OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH HEART FAILURE - INSIGHTS FROM A REAL-WORLD POPULATION FOLLOWED IN A REGIONAL HOSPITAL

- PO 117 PREDICTION OF INDIVIDUAL LIFETIME RISK IN PORTUGUESE PATIENTS WITH HFREF
- PO 118 FIBRINOGEN IS ASSOCIATED TO INCREASED ARTERIAL STIFFNESS ON HYPERTENSIVE INDIVIDUALS
- PO 119 THE GENETIC POLYMORPHISM OF ALPHA-ADDUCIN 1 IS ASSOCIATED WITH INCREASED ARTERIAL STIFFNESS IN A DIABETIC POPULATION
- PO 120 HOLTER MONITORING FINDINGS IN NEUROMUSCULAR DISORDERS: FREQUENCY AND IMPORTANCE IN CLINICAL MANAGEMENT
- PO 121 RECURRENT TRANSFUSION THERAPY IN SICKLE CELL DISEASE - ARE THERE RELEVANT ECHOCARDIOGRAPHIC DIFFERENCES IN THE EVALUATION OF THESE PATIENTS?
- PO 122 AJMALINE TESTING IN BRUGADA SYNDROME: A COMPARATIVE ANALYSIS OF DIAGNOSTIC PROTOCOLS AND CLINICAL OUTCOMES ACROSS TWO HOSPITALS
- PO 123 PROGNOSTIC IMPACT OF COMPLETE REVASCLARIZATION DURING INDEX HOSPITALIZATION FOR NON-ST ELEVATION MYOCARDIAL INFARCTION
- PO 124 IMPACT OF CANCER HISTORY ON NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (NSTEMI) PROGNOSIS - A PROPENSITY-SCORE MATCHING (PSM) ANALYSIS
- PO 125 EVALUATION OF DIAGNOSTIC ACCURACY OF THE MODIFIED CHA2DS2-VASC SCORE IN PREDICTING OBSTRUCTIVE CORONARY DISEASE AMONG PATIENTS SUSPECTED OF CHRONIC CORONARY SYNDROME
- PO 126 MODERATE TO SEVERE CHRONIC KIDNEY DISEASE AND ACUTE CORONARY SYNDROMES - APPROACH AND OUTCOMES
- PO 127 RISK STRATIFICATION OF CHEST PAIN IN A PORTUGUESE EMERGENCY DEPARTMENT: IS THE HEART SCORE APPROPRIATE?
- PO 128 EXPLORING THE SIGNIFICANCE OF PROCALCITONIN IN CARDIOGENIC SHOCK FOR THE PREDICTION OF INFECTION AND MORTALITY OUTCOMES
- PO 129 LIPOPROTEIN (A): WHAT ROLE IN LONG-TERM PROGNOSIS OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
- PO 130 GENE-GENE AND GENE-ENVIRONMENT INTERACTION IN CORONARY ARTERY DISEASE RISK
- PO 131 PROGNOSTIC IMPACT OF ESTIMATED GLOMERULAR FILTRATION RATE IN PATIENTS WITH ACUTE CORONARY SYNDROME - WHICH IS THE BEST FORMULA?
- PO 132 EARLY POST-DISCHARGE NTPROBNP LEVELS AS A MARKER OF PROGNOSIS IN HEART FAILURE PATIENTS
- PO 133 UREA LEVELS AT ADMISSION: A FORGOTTEN YET CRUCIAL PROGNOSTIC MARKER IN HOSPITALIZED HEART FAILURE PATIENTS
- PO 134 HIGH-FLOW NASAL CANNULA VERSUS CONVENTIONAL OXYGEN THERAPY IN ACUTE HEART FAILURE: A META-ANALYSIS
- PO 135 PERFORMANCE OF FENNIX SCORE IN POST-DISCHARGE HEART FAILURE APPOINTMENT: A PREDICTOR OF FUTURE HOSPITALIZATION
- PO 136 ACETAZOLAMIDE EFFICACY AND SAFETY IN PATIENTS WITH ACUTE HEART FAILURE WITH VOLUME OVERLOAD: A SYSTEMATIC REVIEW AND META-ANALYSIS.
- PO 137 WHAT DOES THE RATIO UREA-TO-CREATININE IN HEART FAILURE HOSPITALIZATIONS TELL US?
- PO 138 REAL-WORLD APPLICABILITY OF THE EMERGENCY HEART FAILURE MORTALITY RISK GRADE IN REDUCING HOSPITALIZATION
- PO 139 BEYOND NT-PROBNP: CA-125'S DISTINCTIVE ROLE IN HEART FAILURE - INSIGHTS INTO RIGHT VENTRICULAR PREDOMINANCE AND TRICUSPID REGURGITATION
- PO 140 PATIROMER AS A CORNERSTONE FOR HYPERKALEMIA MANAGEMENT IN SPIRONOLACTONE-UNTREATED PATIENTS - A REAL-WORLD PERSPECTIVE
- PO 141 BEYOND GUIDELINES: ACHIEVING RISK FACTORS THERAPEUTIC GOALS THROUGH A STRUCTURED FOLLOW-UP PROGRAM
- PO 142 DIGITAL SELF-REPORTED CARDIOVASCULAR RISK FACTORS IN A SAMPLE OF THE PORTUGUESE POPULATION - PRELIMINARY RESULTS FROM THE RADICAL STUDY
- PO 143 WHICH IS BETTER FOR PREDICTING AND DISCRIMINATING CARDIOVASCULAR EVENTS: A TRADITIONAL RISK SCORE, A CALCIUM SCORE OR A GENETIC RISK SCORE?
- PO 144 SECONDARY PREVENTION IN YOUNG PATIENTS AFTER ACUTE ST SEGMENT ELEVATION MYOCARDIAL INFARCTION: MISSING THE GOALS AND SUFFERING THE PENALTIES.
- PO 145 CARDIOGAP: BRIDGING THE GAP BETWEEN PATIENT IDENTIFICATION AND THERAPY IMPLEMENTATION IN CARDIOVASCULAR RISK
- PO 146 ENHANCING CARDIOVASCULAR HEALTH POST-ACUTE CORONARY SYNDROME: A SPECIALIZED FOLLOW-UP PROGRAM

- PO 147** RISK FACTOR ANALYSIS OF PERMANENT PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 148** UNMET NEEDS IN TRANSCATHETER AORTIC VALVE REPLACEMENT: A NOVEL TELEMETRY PATCH FOR MONITORING CONDUCTION DISTURBANCES
- PO 149** DE NOVO CONDUCTION DISTURBANCES AFTER TAVI: WHAT TO EXPECT?
- PO 150** NON-CORONARY CUSP ASYMMETRICAL CALCIFICATION AS A PREDICTOR OF COMPLETE ATRIOVENTRICULAR BLOCK POST-TAVI
- PO 151** NEW-ONSET LEFT BUNDLE BRANCH BLOCK AFTER TAVI: UNVEILING ITS TRUE CLINICAL IMPACT
- PO 152** IMPACT OF RHYTHM DISTURBANCES IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION UNDERGOING TAVI
- PO 153** FTO RS8050136 C>A VARIANT IS A RISK FACTOR FOR METABOLIC SYNDROME IN A PORTUGUESE POPULATION
- PO 154** METABOLOMICS AND POOR CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HEART FAILURE (HF): A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 155** LEFT EJECTION FRACTION FOLLOWING CHRONIC TOTAL CORONARY OCCLUSION RECANALIZATION - APPROPRIATE PATIENT SELECTION NEEDED?
- PO 156** CORRELATION BETWEEN AUTOMATICALLY OBTAINED LONGITUDINAL SHORTENING OF THE LEFT VENTRICLE AND THE PRESENCE OF LATE ENHANCEMENT ON CMR
- PO 157** IS HOMOCYSTEINE AN INDEPENDENT RISK FACTOR FOR SUBCLINICAL CORONARY ATHEROSCLEROSIS IN ASYMPTOMATIC INDIVIDUALS?
- PO 158** REVASCULARIZATION STRATEGIES IN ELDERLY PATIENTS WITH MULTIVESSEL DISEASE: A COMPARATIVE ANALYSIS OF COMPLETE AND INCOMPLETE INTERVENTIONS
- PO 159** LONG-TERM SURVIVAL AFTER CORONARY ARTERY BYPASS GRAFTING: COMPARING BILATERAL VERSUS SINGLE INTERNAL MAMMARY ARTERY IN A WOMEN COHORT
- PO 160** CORONARY ARTERY BYPASS GRAFTING COULD EXTEND SURVIVAL IN OCTOGENARIAN PATIENTS
- PO 161** BRIDGING THE GAP: A COMPREHENSIVE META-ANALYSIS ON SURGICAL REVASCULARIZATION FOR CHRONIC CORONARY TOTAL OCCLUSIONS
- PO 162** LONG-TERM OUTCOMES OF DELAYED PERCUTANEOUS INTERVENTION VERSUS SAPHENOUS VEIN GRAFT FOR REVASCULARIZING THE RIGHT CORONARY ARTERY
- PO 163** PREDICTORS OF PROLONGED HOSPITALIZATION AFTER CARDIAC SURGERY: INSIGHTS FROM A RETROSPECTIVE STUDY
- PO 164** THE IMPACT OF SEX ON LONG-TERM SURVIVAL AFTER CORONARY ARTERY BYPASS GRAFTING: 19-YEARS OF FOLLOW-UP
- PO 165** VIABAHN STENTS FOR TREATING TAVI-RELATED VASCULAR ACCESS COMPLICATIONS - A SINGLE-CENTRE EXPERIENCE
- PO 166** SECONDARY ACCESS IN TAVR: ENHANCING SAFETY AND SIMPLIFYING VASCULAR COMPLICATIONS RESOLUTION
- PO 167** VASCULAR COMPLICATIONS AFTER TRANSFEMORAL TRANSCATHETER AORTIC VALVE IMPLANTATION IN PATIENTS WITH SMALL PERIPHERAL VESSELS
- PO 168** VALVE-IN-VALVE TRANSCATHETER AORTIC VALVE IMPLANTATION IN PATIENTS WITH FAILED BIOPROSTHETIC AORTIC VALVES: AN ANALYSIS OF SAFETY, FEASIBILITY AND CLINICAL OUTCOMES.
- PO 169** LONG-TERM CLINICAL AND IMAGING OUTCOMES OF PATIENTS UNDERGOING PERCUTANEOUS FEMORAL INTERVENTION FOLLOWING TAVI-RELATED VASCULAR ACCESS COMPLICATIONS
- PO 170** MANTA VASCULAR CLOSURE DEVICE: CARDIOVASCULAR RISK FACTORS AND COMPLICATIONS IN A SINGLE-CENTER STUDY
- PO 171** OPTIMIZING CARDIAC REHABILITATION ADHERENCE: UNVEILING THE POTENTIAL OF REMOTE CARDIAC TELEREHABILITATION
- PO 172** IMPROVED EXERCISE CAPACITY AND CARDIAC EVENTS AFTER REHABILITATION IN POST-ACUTE CORONARY SYNDROME PATIENTS.
- PO 173** BEYOND PHASE 2: THE IMPACT OF PHASE 3 CARDIAC REHABILITATION ON PHYSICAL ACTIVITY
- PO 174** CHRONOTROPIC INCOMPETENCE - STILL ON TIME TO MAKE A DIFFERENCE ?
- PO 175** CARDIOVASCULAR REHABILITATION - DETERMINANTS OF LONG-TERM OUTCOMES
- PO 176** POST-CARDIAC REHABILITATION CONCERNS: CAN CHRONIC HEART FAILURE PATIENTS SUSTAIN HEALTH GAINS DURING PHASE III?
- PO 177** CONTRIBUTES OF GENETIC TESTING TO UNDERSTANDING THE AETIOLOGY OF SUDDEN CARDIAC ARREST: 4-YEAR EXPERIENCE OF GENETIC LABORATORY
- PO 178** UTILITY OF RESTING ELECTROCARDIOGRAM IN SCREENING AND RISK STRATIFICATION OF BRUGADA SYNDROME

- PO 179 SHANGAI SCORE AS AN OUTCOME PREDICTOR FOR BRUGADA SYNDROME PATIENTS
- PO 180 EFFECT OF SGLT2 INHIBITORS IN SUSTAINED VENTRICULAR TACHYARRHYTHMIAS IN PATIENTS WITH IMPLANTABLE CARDIOVERTER DEFIBRILLATORS FOR PRIMARY PREVENTION
- PO 181 PROGNOSTIC VALUE OF PROGRAMMED ELECTRICAL STIMULATION IN BRUGADA SYNDROME: A SINGLE-CENTER STUDY.
- PO 182 ROLE OF PROGRAMMED VENTRICULAR STIMULATION IN RISK STRATIFICATION OF TYPE 1 ASYMPTOMATIC BRUGADA PATIENTS
- PO 183 PROGNOSTIC SIGNIFICANCE OF PROGRAMMED VENTRICULAR STIMULATION IN BRUGADA PATIENTS
- PO 184 USEFULNESS OF SUBCUTANEOUS IMPLANTABLE LOOP RECORDER IN BRUGADA SYNDROME: A SINGLE CENTER EXPERIENCE.
- PO 185 PREDICTORS OF IMPLANTABLE CARDIO-DEFIBRILLATOR ACTIVATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY AT PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH
- PO 186 INVASIVE TREATMENT WITHOUT STENTING IN ACUTE MYOCARDIAL INFARCTION: "NO STENT" EXPERIENCE IN SINGLE CENTRE
- PO 187 INTRAVASCULAR LITHOTRIPSY EFFECTIVENESS AND SAFETY IN A LARGE REAL-WORLD COHORT
- PO 188 PHYSIOLOGY VERSUS ANGIOGRAPHY-GUIDED CORONARY ARTERY BYPASS GRAFTING: A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 189 AMBULATORY PCI ANALYSIS - INSIGHTS FROM SINGLE CENTER EXPERIENCE
- PO 190 PERCUTANEOUS TREATMENT OF SAPHENOUS VEIN GRAFTS- A REAL LIFE ANALYSIS
- PO 191 LONG-TERM OUTCOMES OF A DEDICATED CHRONIC TOTAL OCCLUSION - PERCUTANEOUS CORONARY INTERVENTION (CTO-PCI) PROGRAM
- PO 192 SAME DAY DISCHARGE FOR PERCUTANEOUS CORONARY INTERVENTION - A 4-YEAR SINGLE-CENTER EXPERIENCE
- PO 193 LONG AND MIXT/NON-CALCIFIED PLAQUES AS PREDICTORS OF FUNCTIONALLY SIGNIFICANT CORONARY ARETRY DISEASE
- PO 194 BIOABSORBABLE VASCULAR SCAFFOLDS IN CLINICAL PRACTICE: NOT AS BAD AS ONE MIGHT EXPECT
- PO 195 IMPACT OF RIGHT VENTRICULAR DIMENSION AND FUNCTION ON OUTCOMES IN PATIENTS UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY
- PO 196 LEFT BUNDLE BRANCH AREA PACING: A PARADIGM SHIFT IN CARDIAC RESYNCHRONIZATION THERAPY
- PO 197 CLINICAL EFFICIENCY AND DURABILITY OF THE EPICARDIAL LEFT VENTRICULAR LEADS IN CARDIAC RESYNCHRONIZATION THERAPY.
- PO 198 PREDICTORS OF NON-RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY
- PO 199 ALIGNING HUMAN AND MACHINE - PREDICTORS OF SUPER-RESPONSE TO CRT
- PO 200 IMPROVEMENT OF FUNCTIONAL MITRAL REGURGITATION FOLLOWING CARDIAC RESYNCHRONIZATION THERAPY: PREDICTORS AND CLINICAL OUTCOMES
- PO 201 IMPACT OF ATRIAL FIBRILLATION ON MORTALITY AND RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE: A RETROSPECTIVE ANALYSIS
- PO 202 FROM REDUCED TO NORMAL LEFT VENTRICULAR EJECTION FRACTION: WHAT MAKES A SUPER-RESPONDER TO CRT?
- PO 203 MITRAL REGURGITATION IN HEART FAILURE PATIENTS UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY - DOES IT AFFECTS CLINICAL OUTCOMES?
- PO 204 DECODING THE COMPLEXITY OF ATRIAL FIBRILLATION: UNVEILING DISTINCT PHENOTYPES OF VOLTAGE AND CONDUCTION VELOCITY
- PO 205 ELECTRICAL CARADIOVERSION AND ATRIAL FIBRILLATION RECURRENCE: THE PROGNOSTIC VALUE OF P WAVE ANALYSIS
- PO 206 THE NOWADAYS IMPACT OF THE PRESENCE OF ATRIAL FIBRILLATION IN THE PROGNOSIS OF PATIENTS WITH ACUTE CORONARY SYNDROME
- PO 207 USE OF SMARTWATCHES FOR ATRIAL FIBRILLATION DETECTION: A SYSTEMATIC REVIEW.
- PO 208 BIOPHYSICAL PARAMETERS OF PULMONARY VEIN ISOLATION WITH VERY HIGH-POWER SHORT-DURATION COMPARED TO CONVENTIONAL RADIOFREQUENCY ABLATION GUIDED BY ABLATION INDEX.
- PO 209 POSTERIOR WALL ISOLATION IN PERSISTENT ATRIAL FIBRILLATION: PULSED-FIELD ABLATION VS. RADIOFREQUENCY
- PO 210 INTERTAK PROGNOSTIC SCORE - A USEFUL TOOL TO PREDICT MORTALITY IN TAKOTSUBO SYNDROME?
- PO 211 THE PORTUGUESE MINOCA PATIENTS: INSIGHTS FROM A MULTICENTRE NATIONAL REGISTRY ANALYSIS
- PO 212 COEXISTENCE AND PROGNOSTIC IMPACT OF CORONARY ARTERY DISEASE IN TAKOTSUBO SYNDROME

- PO 213 CARDIAC MAGNETIC RESONANCE ACCESS AND CLINICAL RELEVANCE IN MINOCA: INSIGHTS FROM A TERTIARY CENTER EXPERIENCE
- PO 214 IMPACT OF NEW-ONSET ATRIAL FIBRILLATION ON PROGNOSIS IN TAKOTSUBO SYNDROME
- PO 215 CAN WE PREDICT IN-HOSPITAL COMPLICATIONS IN TAKOTSUBO SYNDROME?
- PO 216 CORRELATING CARDIOPULMONARY EXERCISE TESTING AND RIGHT HEART CATHETERIZATION PARAMETERS IN ADVANCED HEART FAILURE: INSIGHTS FOR PATIENT EVALUATION
- PO 217 O₂ CONSUMPTION OVERSHOOT IN PATIENTS WITH HEART FAILURE: CROSSING THE LINE.
- PO 218 LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN IS ASSOCIATED WITH INVASIVE FILLING PRESSURES AND CARDIAC OUTPUT IN THE AMBULATORY SETTING: INSIGHTS FROM THE CARDIOMEMS™
- PO 219 UNVEILING THE INTERPLAY OF PULMONARY HYPERTENSION PARAMETERS FROM RIGHT HEART CATHETERIZATION WITH CARDIOPULMONARY EXERCISE TESTING IN HEART FAILURE PATIENTS
- PO 220 EXERCISE STRESS TESTING RECOVERY KINETICS: THE FORGOTTEN PHASE.
- PO 221 BEYOND BEATS: AN ANALYSIS OF HEMODYNAMICS AND EXERCISE CAPACITY IN HEART FAILURE PATIENTS WITH ATRIAL FIBRILLATION
- PO 222 RIGHT CARDIOVASCULAR REMODELLING AND REVERSE REMODELLING DURING PREGNANCY AND POSTPARTUM
- PO 223 ECG IMAGING FOR REAL-TIME ASSESSMENT OF VENTRICULAR SYNCHRONY IN PHYSIOLOGICAL PACING
- PO 224 PHYSICAL ACTIVITY LEVELS AND SEDENTARY BEHAVIOUR PATTERNS IN PATIENTS ATTENDING A PHASE III CARDIAC REHABILITATION PROGRAM: ARE THERE DIFFERENCES BETWEEN MEN AND WOMEN?
- PO 225 CARDIOMYOPATHIES: THE IMPORTANCE OF GENETIC TESTING IN THE ELDERLY
- PO 226 CUSTOS DA IMPLANTAÇÃO PERCUTÂNEA DE VÁLVULA AÓRTICA E DO SEU COMPARADOR
- PO 227 HANDGRIP STRENGTH AND MUSCLE MASS GAINS IN PHASE III CARDIAC REHABILITATION PATIENTS - IMPACT OF WEEKLY EXERCISE TRAINING FREQUENCY
- PO 228 MANUAL THROMBUS ASPIRATION - 12-YEAR SINGLE CENTRE EXPERIENCE
- PO 229 PRIMARY PCI IN A REGIONAL CENTRE - 7 YEARS OF CHANGE AND IMPROVEMENT
- PO 230 LONG TERM BETA-BLOCKERS AFTER ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN PATIENTS WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION
- PO 231 PRIMARY PCI IN A REGIONAL CENTRE - PANDEMIC IMPACT
- PO 232 MID-RANGE EJECTION FRACTION AFTER STEMI: DIFFERENT APPLES IN THE SAME BASKET
- PO 233 GENDER DIFFERENCE IN REFERRAL PATHWAY IN PRIMARY PCI
- PO 234 PROGNOSTIC IMPLICATIONS OF P2Y12 INHIBITOR PRETREATMENT IN NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROMES UNDERGOING LATE INVASIVE STRATEGY - A NATIONAL REGISTRY ANALYSIS
- PO 235 EFFICACY AND SAFETY OF USING 3 VS 12-MONTH ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION: META-ANALYSIS OF RANDOMIZED CONTROLLED CLINICAL TRIALS
- PO 236 PRECISE DAPT SCORE FOR PREDICTION OF OUTCOMES IN PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION FOR PROXIMAL LEFT ANTERIOR DESCENDING ARTERY.
- PO 237 TRIPLE ANTITHROMBOTIC THERAPY IN ACUTE CORONARY SYNDROME IN PATIENTS WITH MODERATE-HIGH ISCHEMIC RISK: HOW TO DEFINE THE DURATION OF TREATMENT TAKING INTO ACCOUNT THE OUTCOME?
- PO 238 DEVELOPMENT OF A CLINICAL RISK SCORE FOR EARLY LEFT VENTRICULAR THROMBUS PREDICTION FOLLOWING ANTERIOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
- PO 239 STEMI DUAL ANTIPLATELET PRETREATMENT - PORTUGUESE MULTICENTER EXPERIENCE
- PO 240 REAL-WORLD IMPACT OF EARLY QUADRUPLE THERAPY IN HFREF: A COMPARATIVE ANALYSIS OF SEQUENTIAL VS. SIMULTANEOUS APPROACHES
- PO 241 HEART FAILURE ETIOLOGY AND ARNI+SGLT2I INITIATION MAY INFLUENCE ICD IMPLANTATION TIMING
- PO 242 QUADRUPLE THERAPY AT DISCHARGE: ENHANCING CLINICAL TRAJECTORIES IN DECOMPENSATED HEART FAILURE WITH REDUCED EJECTION FRACTION
- PO 243 REAL-WORLD DAPAGLIFLOZIN AND CONCOMITANT MEDICATION TREATMENT PATTERNS IN PORTUGUESE PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
- PO 244 BEYOND ASSUMPTIONS: NT-PROBNP RISE AND DIURETIC STRATEGIES IN HFREF THERAPY UP-TITRATION
- PO 245 VERICIGUAT ELIGIBILITY IN HEART FAILURE: EARLY POST-DISCHARGE ASSESSMENT
- PO 246 ASSESSMENT OF SUBCLINICAL HYPERVOLEMIA BY BIOIMPEDANCE SPECTROSCOPY IN HEART FAILURE

- PO 247 INTERMITTENT LEVOSIMENDAN CYCLES: A SINGLECENTRE CLINICAL EXPERIENCE
- PO 248 SLIDING DOWN A SLOPE - THE PROGNOSTIC VALUE OF DIFFERENT METHODS OF MEASURING VE/VCO₂ IN HEART FAILURE
- PO 249 "I NEED HELP": UNLEASHING THE FULL POTENTIAL OF THE ACRONYM FOR THE MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
- PO 250 HOME ADMINISTRATION OF LEVOSIMENDAN IN PATIENTS WITH ADVANCED HEART FAILURE - THE LEVO-HOME PILOT PROJECT
- PO 251 INTERMITTENT OUTPATIENT ADMINISTRATION OF LEVOSIMENDAN IN PATIENTS WITH ADVANCED HEART FAILURE: IS IT ENOUGH?
- PO 252 AGE-RELATED IMPLICATIONS IN GUIDELINE-DIRECTED MEDICAL THERAPY UP-TITRATION FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: A RETROSPECTIVE SINGLE-CENTER STUDY
- PO 253 BEYOND 3 MONTHS: UNRAVELING THE PROLONGED IMPACT OF OPTIMIZED MEDICAL THERAPY ON LVEF AND ICD IMPLANTATION IN HFREF PATIENTS
- PO 254 ASSOCIATION BETWEEN PHYSICIAN-PERCEIVED FUNCTIONAL CLASS AND FUNCTIONAL CAPACITY MEASURED BY EXERCISE STRESS TEST IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
- PO 255 REMOTE MONITORING OF CARDIAC IMPLANTABLE ELECTRONIC DEVICES FOR PREDICTING ACUTE CLINICAL DECOMPENSATION EVENTS IN HEART FAILURE PATIENTS
- PO 256 THE EFFECT OF INTRAVENOUS IRON-CARBOHYDRATE COMPLEXES ON QUALITY OF LIFE IN PATIENTS WITH ACUTE VS CHRONIC HEART FAILURE - A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 257 THE CLINICAL VALUE OF BIOELECTRICAL PHASE ANGLE IN HEART FAILURE
- PO 258 PREVALENCE OF ECHOCARDIOGRAPHIC FINDINGS COMPATIBLE WITH PRESERVED EJECTION FRACTION HEART FAILURE IN A REAL-WORLD PRACTICE
- PO 259 PREDICTION OF WAIT TIMES IN HEART TRANSPLANTATION IN PORTUGAL
- PO 260 CLINICAL OUTCOMES OF IMPLANTABLE CARДИOVERTER DEFIBRILLATORS IN HEART FAILURE: A COMPARATIVE ANALYSIS BETWEEN ISCHEMIC AND NON-ISCHEMIC CARDIOMYOPATHY PATIENTS
- PO 261 ASSOCIATION BETWEEN IMPAIRED KIDNEY FUNCTION AND WORSE RESPONSE TO LEVOSIMENDAN TREATMENT
- PO 262 TWO YEARS OF ACTIVITY AT A HEART FAILURE DAY HOSPITAL IN A PRIVATE HOSPITAL: A REAL-WORLD PORTRAIT
- PO 263 IMPACT OF ACTIVE INTERVENTION IN HIGH-RISK HEART FAILURE PATIENTS UNDER A TEAM-BASED REMOTE MONITORING UNIT
- PO 264 ATYPICAL RIGHT ATRIUM FLUTTERS
- PO 265 EVALUATION OF THE USE OF OPEN WINDOW MAPPING WITH HIGH DENSITY CATERER IN PATIENTS WITH WOLFF-PARKINSON-WHITE IN A TERTIARY CARE UNIT
- PO 266 RADIOFREQUENCY CATHETER ABLATION OF ANTEROSEPTAL AND MIDSEPTAL ACCESSORY PATHWAYS IN THE ERA OF ELECTROANATOMIC MAPPING SYSTEMS AND IRRIGATED CATHETERS
- PO 267 BIATRIAL FLUTTERS UNCOMMON CIRCUITS REQUIRING TAILORED ABLATION APPROACH
- PO 268 INITIAL EXPERIENCE WITH A NOVEL TEMPERATURE-CONTROLLED RADIOFREQUENCY CATHETER ABLATION FOR THE TREATMENT OF ATRIAL FLUTTER
- PO 269 ACCESSORY PATHWAY ABLATION IN WOLFF-PARKINSON-WHITE SYNDROME: A DECADE OF EXPERIENCE
- PO 270 LEFT MAIN PERCUTANEOUS INTERVENTION FOR MYOCARDIAL INFARCTION: A TERTIARY CENTRE RETROSPECTIVE STUDY
- PO 271 PERCUTANEOUS REVASCULARIZATION OF LEFT MAIN CORONARY ARTERY IN DIABETIC PATIENTS
- PO 272 COMPREHENSIVE ASSESSMENT OF LEFT MAIN CORONARY ARTERY STENOSIS UTILIZING PRESSURE WIRE: A RETROSPECTIVE ANALYSIS
- PO 273 A DECADE OF URGENT AND EMERGENT UNPROTECTED LEFT MAIN STEM PERCUTANEOUS CORONARY INTERVENTION: OUTCOMES FROM A PORTUGUESE CARDIAC CENTER
- PO 274 LEFT MAIN CORONARY ARTERY ANGIOPLASTY IN PATIENTS WITH NON-COMPLEX CORONARY ARTERY DISEASE
- PO 275 THE INFLUENCE OF CARDIOVASCULAR RISK FACTORS ON RESTENOSIS AND MORTALITY FOLLOWING PERCUTANEOUS CORONARY INTERVENTION FOR LEFT MAIN DISEASE
- PO 276 LEFT BUNDLE BRANCH AREA PACING USING STYLET-DRIVEN PACING LEADS- EXPERIENCE OF ONE CENTER
- PO 277 SYMPTOM-RHYTHM CORRELATION OF IMPLANTABLE LOOP RECORDERS IN PATIENTS WITH SYNCOPE/PRESYNCOPE
- PO 278 LONG-TERM RESULTS OF CARDIONEUROABLATION EVALUATED BY IMPLANTABLE LOOP RECORDER

- PO 279** LONG-TERM IMPACT OF PACEMAKER IMPLANTATION AFTER TAVI: A SUBGROUP ANALYSIS ACCORDING TO PREVIOUS INTRAVENTRICULAR CONDUCTION DISTURBANCES
- PO 280** UNRAVELING THE STORY OF HUNDREDS OF SYNCOPES AND PRE-SYNCOPES
- PO 281** MID-TERM VENTRICULAR PACING PERCENTAGE IN PATIENTS REQUIRING PACEMAKER IMPLANTATION FOLLOWING TAVR: INSIGHTS FROM A LARGE SINGLE-CENTER EXPERIENCE
- PO 282** LEFT BUNDLE BRANCH AREA PACING IN TAVI PATIENTS: A FEASIBLE ALTERNATIVE?
- PO 283** THE LEARNING CURVE OF LEFT BUNDLE BRANCH AREA PACING: FEASIBILITY, SAFETY AND ACUTE SUCCESS RATES - A SINGLE-CENTER EXPERIENCE
- PO 284** LEADLESS PACEMAKER - LEAD PARAMETERS STABILITY AND BATTERY LONGEVITY IN THE MID-TERM FOLLOW-UP
- PO 285** COMORBIDITY AND PROGNOSIS IN OCTOGENARIANS WITH INFECTIVE ENDOCARDITIS
- PO 286** INFECTIVE ENDOCARDITIS - SEX DIFFERENCES
- PO 287** LANDSCAPE OF INFECTIVE ENDOCARDITIS IN A PORTUGUESE TERTIARY CENTER: DEMOGRAPHIC TRENDS, RISK PROFILES AND CLINICAL VARIABILITY
- PO 288** RELATIVE CONTRIBUTION OF IMAGING TECHNIQUES FOR THE CONTEMPORARY DIAGNOSIS OF INFECTIVE ENDOCARDITIS: A SINGLE-CENTER EXPERIENCE
- PO 289** INFECTIVE ENDOCARDITIS RISK IN PATIENTS WITH BICUSPID AORTIC VALVE: SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 290** PREDICTORS OF EMBOLIC EVENTS IN INFECTIVE ENDOCARDITIS - REALITY IN PORTUGUESE CENTER
- PO 291** UNDERSCORING THE NEED FOR INFECTIVE ENDOCARDITIS RISK STRATIFICATION AND MANAGEMENT
- PO 292** IMPACT OF ACUTE HEART FAILURE IN INFECTIVE ENDOCARDITIS: A REAL-WORLD STUDY
- PO 293** INFECTIVE ENDOCARDITIS IN ELDERLY - PREDICTORS OF 1 YEAR MORTALITY
- PO 294** TIME-TRENDS IN THE DECISION OF A PRIMARY PREVENTION STRATEGY IMPLEMENTATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- PO 295** CLINICAL OUTCOMES IN A POPULATION WITH HYPERTROPHIC CARDIOMYOPATHY AND MYBPC3 GENE DISEASE: THE SHORT VERSION OF A LONG HISTORY.
- PO 296** MYOCARDIAL BRIDGING IN HYPERTROPHIC CARDIOMYOPATHY: PREVALENCE, CHARACTERISTICS, AND CLINICAL IMPLICATIONS
- PO 297** ASSESSMENT OF ECG AS A SCREENING TOOL FOR HYPERTROPHIC CARDIOMYOPATHY: ADEQUACY AND PHENOTYPIC CORRELATIONS
- PO 298** MAVACAMTEN IN A REAL-WORLD HYPERTROPHIC CARDIOMYOPATHY (HCM) POPULATION: HOW MANY MAY BE ELIGIBLE?
- PO 299** CLINICAL PROFILE AND OUTCOMES OF PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY ASSOCIATED WITH MUTATIONS IN THE MYH7 GENE: A LONG LONGITUDINAL FOLLOW UP STUDY
- PO 300** PREDICTION OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- PO 301** HYPERTROPHIC CARDIOMYOPATHY AND CORONARY ARTERY DISEASE: PREVALENCE, CHARACTERISTICS, AND IMPLICATIONS IN THE CONTEXT OF EVOLVING PHYSICAL EXERCISE RECOMMENDATIONS
- PO 302** THE PHENOTYPIC EXPRESSION OF HYPERTROPHIC CARDIOMYOPATHY - INSIGHTS FROM A POPULATION WITH PATHOGENIC MUTATIONS IN THE MYBPC3 GENE
- PO 303** COMPARISON OF RADIOMIC FEATURE STABILITY BETWEEN HUMAN SEGMENTATIONS AND AUTOMATIC SEGMENTATION TOOLS.
- PO 304** CT-RADIOMIC FEATURES OF EPICARDIAL ADIPOSE TISSUE IN AF RECURRENCE AFTER CATHETER ABLATION
- PO 305** BEYOND EUROSCORE II - THE INTERPLAY BETWEEN EUROSCORE II AND AORTIC CALCIFICATION AS PREDICTORS OF CLINICAL OUTCOMES IN POSTOPERATIVE CARDIAC SURGERY
- PO 306** RELATIONSHIP BETWEEN THE NEW SCORE2-DIABETES AND CORONARY ATHEROSCLEROTIC BURDEN - A CORONARY CALCIUM SCORE CORRELATION STUDY
- PO 307** CAN AORTIC CALCIUM SCORE PREDICT NEW CONDUCTION DISTURBANCES IN POS-TRANSCATHETER AORTIC VALVE IMPLANTATION?
- PO 308** THE ROLE OF PERICARDIAL FLUID CT RADIOMIC ANALYSIS TO DIFFERENTIATE EXUDATE FROM TRANSUDATE.
- PO 309** PERCUTANEOUS CORONARY REVASCULARIZATION TIMING IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 310** TAVI VS AORTIC VALVE REPLACEMENT SURGERY: COMPARISON OF IN-HOSPITAL OUTCOMES IN PATIENTS WITH SEVERE AORTIC STENOSIS

- PO 311 CLINICAL INSIGHTS: ULTRASOUND-GUIDED FEMORAL PUNCTURE IN TRANSCATHETER AORTIC VALVE REPLACEMENT - A COMPREHENSIVE ANALYSIS OF VASCULAR COMPLICATIONS AND MORTALITY RATES
- PO 312 PREVALENCE, PREDICTORS AND PROGNOSTIC SIGNIFICANCE OF ACUTE KIDNEY RECOVERY FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 313 ENVIRONMENTAL IMPACT OF PERCUTANEOUS AORTIC VALVE IMPLANTS. PROCEDURE ASSESSMENT
- PO 314 ECMO-RELATED VASCULAR COMPLICATIONS: A SINGLE-CENTER EXPERIENCE IN A PORTUGUESE TERTIARY HOSPITAL
- PO 315 SARCOPENIC OBESITY - A HIDDEN PROBLEM IN CARDIOVASCULAR RISK
- PO 316 PREVALENCE OF ELIGIBILITY CRITERIA FOR SEMAGLUTIDE ACCORDING TO THE SELECT TRIAL IN A PORTUGUESE COHORT OF ACUTE CORONARY SYNDROME
- PO 317 EXCEEDING THE THRESHOLDS: CHARACTERIZATION AND CLINICAL IMPACT OF THE THIRD VENTILATORY THRESHOLD IN PATIENTS WITH HEART FAILURE
- PO 318 EXERCISE INTENSITY PRESCRIPTION IN HEART FAILURE PATIENTS: COMPARISON OF DIFFERENT PHYSIOLOGICAL PARAMETERS
- PO 319 THE IMPACT OF CARDIAC REHABILITATION ON MUSCLE STRENGTH - A CRUCIAL ELEMENT OF FUNCTIONAL CAPACITY
- PO 320 SUDDEN CARDIAC DEATH IN ATHLETES: A 20-YEAR ANALYSIS IN PORTUGAL
- PO 321 ARNI TREATMENT IN ADULTS WITH TETRALOGY OF FALLOT - A SINGLE-CENTRE EXPERIENCE
- PO 322 THE DUAL CHALLENGE: UNDERSTANDING AND MANAGING PULMONARY HYPERTENSION IN CONGENITAL HEART DEFECTS
- PO 323 PREDICTORS OF SUPRAVENTRICULAR ARRHYTHMIAS IN ADULTS WITH EBSTEIN ANOMALY
- PO 324 EVALUATION OF FETAL CARDIAC FUNCTION IN GESTATIONAL DIABETES MELLITUS BY TWO-DIMENSIONAL SPECKLE-TRACKING TECHNOLOGY
- PO 325 SACUBITRIL/VALSARTAN IN ADULTS WITH CONGENITAL HEART DISEASE AND DEPRESSED VENTRICLE FUNCTION
- PO 326 PULMONARY REGURGITATION IN TETRALOGY OF FALLOT - THE EXPERIENCE OF A SINGLE TERTIARY CENTER
- PO 327 SEX DIFFERENCES IN ECHOCARDIOGRAPHIC PARAMETERS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND PRESERVED EJECTION FRACTION.
- PO 328 DEMOGRAPHIC AND ANGIOGRAPHIC CHARACTERISTICS IN PREMATURE CASES OF ACUTE CORONARY SYNDROME
- PO 329 ACUTE CORONARY SYNDROMES: MEN AND WOMEN - SAME SPECIES, SAME DISEASE, SAME MANIFESTATION?
- PO 330 IS THE CARDIOPROTECTIVE EFFECT OF PRE-INFARCTION ANGINA BLUNTED BY AGE?
- PO 331 GENDER DIFFERENCES IN OUTCOMES FOLLOWING ACUTE CORONARY SYNDROME IN YOUNG ADULTS
- PO 332 IMPACT OF ACUTE CULPRIT OCCLUSION IN PATIENTS PRESENTING WITH NON-ST SEGMENT ELEVATION MYOCARDIAL INFARCTION
- PO 333 CORONARY ANGIOGRAPHY IN HIGH-RISK NON-ST-ELEVATION ACUTE CORONARY SYNDROME - THE SOONER THE BETTER?
- PO 334 ARE WE GENDER-BIASED IN PRESCRIPTION PRACTICES? AN ANALYSIS OF THE PORTUGUESE REGISTRY OF ACUTE CORONARY SYNDROMES
- PO 335 COMPARATIVE SAFETY AND EFFICACY OF ROTATIONAL ATHERECTOMY IN NSTE-ACS AND SA PATIENTS: A RETROSPECTIVE STUDY
- PO 336 REVASCULARIZATION STRATEGIES IN ELDERLY PATIENTS WITH ACUTE CORONARY SYNDROMES AND MULTIVESSEL DISEASE: A COMPARATIVE ANALYSIS OF CULPRIT-ONLY VS. COMPLETE REVASCULARIZATION
- PO 337 OUTCOMES OF VALVE-IN-VALVE AND VALVE-IN-RING PROCEDURES FOLLOWING 1.6 YEARS OF FOLLOW-UP
- PO 338 TRICUSPID INTERVENTION FOR SEVERE TRICUSPID REGURGITATION IN PATIENTS WITH CARDIAC IMPLANTABLE ELECTRONIC DEVICES - MANAGEMENT, FATE OF LEADS AND OUTCOMES
- PO 339 IMPACTO DO TEMPO DE ESPERA NOS DOENTES EM LISTA PARA SUBSTITUIÇÃO VALVULAR AÓRTICA
- PO 340 CONSERVATIVE APPROACH FOR SIGNIFICANT VALVULAR HEART DISEASE - HOW GRIM IS THE PROGNOSIS?
- PO 341 PREDICTORS OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH SEVERE AORTIC STENOSIS AWAITING AORTIC VALVE REPLACEMENT
- PO 342 ANTICOAGULATION FOLLOWING VALVE-IN-VALVE, VALVE-IN-RING AND VALVE-IN-MAC - A SYSTEMATIC REVIEW WITH METAANALYSIS
- PO 343 POST- TAVI CARE: ASSESSING THE NEED FOR CARDIAC DEVICE IMPLANTATION
- PO 344 POST-TAVI MYOCARDIAL INJURY: DEFINING A DIAGNOSIS

- PO 345** IMPACT OF TRANSCATHETER AORTIC VALVE IMPLANTATION ON KIDNEY FUNCTION IN PATIENTS WITH SEVERE AORTIC STENOSIS
- PO 346** AORTIC VALVE CALCIFICATION AS A SURROGATE PARAMETER FOR PARAVALVULAR REGURGITATION FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 347** EXPLORING ATRIOVENTRICULAR CONDUCTION DISTURBANCES AND VENTRICULAR PACING RATE IN PATIENTS WITH PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 348** CUSP-OVERLAP TECHNIQUE TO REDUCE PERMANENT PACEMAKER IMPLANTATION RATE AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 349** EXPLORATORY ANALYSIS OF CLINICAL OUTCOMES IN PATIENTS WITH SECONDARY MITRAL REGURGITATION: THE IMPACT OF COAPT TRIAL CRITERIA
- PO 350** INTRODUCTION OF A MINIMALLY INVASIVE MITRAL VALVE PROGRAM. A SINGLE CENTER ANALYSIS.
- PO 351** FUNCTIONAL MITRAL REGURGITATION IMPROVEMENT AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: A COMPREHENSIVE SINGLE-CENTER STUDY
- PO 352** CAN ELDERLY PATIENTS WITH SEVERE MITRAL REGURGITATION BE IDEAL CANDIDATES FOR MITRACLIP?
- PO 353** THE EFFECTS OF MITRACLIP FOR SEVERE MITRAL REGURGITATION ON RIGHT VENTRICULAR FUNCTION AND REMODELLING
- PO 354** MITRAL TRANSCATHETER EDGE-TO-EDGE REPAIR: 10-YEAR EXPERIENCE FROM A TERTIARY CARE CENTER
- PO 355** AUTOMATIC MEASUREMENT OF ATRIAL LONGITUDINAL SHORTENING BY ARTIFICIAL INTELLIGENCE IN CMR IN THE ASSESSMENT OF LEFT ATRIAL FUNCTION IN PATIENTS WITH HCM AND MCD
- PO 356** HISTOPATHOLOGICAL MYOCARDIAL CHANGES IN PATIENTS WITH SEVERE AORTIC STENOSIS REFERRED FOR SURGICAL VALVE REPLACEMENT: A CMR CORRELATION STUDY
- PO 357** SAFETY OF MAGNETIC RESONANCE IMAGING IN PATIENTS WITH COMPATIBLE CARDIAC IMPLANTABLE ELECTRONIC DEVICES: A SAFETY AND ACUTE PERFORMANCE EVALUATION
- PO 358** CARDIOVASCULAR MAGNETIC RESONANCE VS HISTOPATHOLOGIC STUDY FOR BENIGN AND MALIGNANT CARDIAC TUMOURS DIAGNOSIS - A SYSTEMATIC REVIEW AND METANALYSES
- PO 359** CORRELATION BETWEEN ELECTROCARDIOGRAM AND CARDIAC MAGNETIC RESONANCE IMAGING IN ACUTE MYOCARDITIS
- PO 360** AUTOMATIC PARAMETER OBTAINED BY ARTIFICIAL INTELLIGENCE IN CMR FOR THE ASSESSMENT OF LEFT VENTRICULAR FUNCTION IN PATIENTS WITH DILATED AND HYPERTROPHIC CARDIOMYOPATHY
- PO 361** A HOME-BASED CARDIAC REHABILITATION PROGRAM AIMED AT IMPROVING THEIR CARDIAC CONDITION AND FUNCTIONAL CAPACITY IN PATIENTS WITH LVEF
- PO 362** CONTRIBUTOS PARA A VALIDAÇÃO DO CORONARY ARTERY DISEASE EDUCATION QUESTIONNAIRE II PARA PORTUGUÊS EUROPEU
- PO 363** PREVALENCE OF SARCOPENIA IN ELDER PATIENTS WITH HEART FAILURE- AN UNDERDIAGNOSED COMORBIDITY
- PO 364** IS THE BALANCE OF PATIENTS WITH A VENTRICULAR EJECTION FRACTION =40% A VIABLE METRIC FOR ASSESSING THEIR OVERALL HEALTH?
- PO 365** HIGH SCREENING BLOOD PRESSURE IS FOUND IN MOST OBESE PRIMARY SCHOOL CHILDREN FROM THE NORTH OF PORTUGAL: PRELIMINARY RESULTS FROM THE GREAT STUDY.
- PO 366** DESENVOLVIMENTO DE UM SISTEMA M-HEALTH PARA A AUTOGESTÃO DO DOENTE COM INSUFICIÊNCIA CARDÍACA: VIVERCOMIC
- PO 367** SEX DIFFERENCES IN PLASMA LIPIDOMIC PROFILES OF HEALTHY SUBJECTS AND PATIENTS WITH CARDIOVASCULAR DISEASE
- PO 368** HEART FAILURE DISPARITIES BY SEX: A COMPARATIVE ANALYSIS OF A REAL-WORLD POPULATION FOLLOWED IN A REGIONAL HOSPITAL
- PO 369** SEX DIFFERENCES IN LONG-TERM ATTENDANCE AND DROPOUT RATES IN PHASE III CARDIOVASCULAR REHABILITATION PROGRAMS
- PO 370** SEX-RELATED DIFFERENCES IN CONDUCTION DISTURBANCES AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 371** SEX-BASED DIFFERENCES IN INFECTIVE ENDOCARDITIS: A REAL-WORLD STUDY
- PO 372** PREGNANCY AS A MODEL TO EXPLORE STRETCH-INDUCED COMPLIANCE MECHANISM IN PHYSIOLOGICAL HYPERTROPHY
- PO 373** PRECISION IN PROGNOSTICATION: A COMPREHENSIVE COMPARISON OF RISK SCORES IN THE SETTING OF CARDIOGENIC SHOCK

- PO 374** LV REVERSE REMODELING AFTER SAVR IN PATIENTS WITH SEVERE SYMPTOMATIC AORTIC STENOSIS: IMPACT ON THE CLINICAL OUTCOME
- PO 375** MAY ORAL IRON PLAY A ROLE IN HFREF WITH IRON DEFICIENCY? A SECONDARY ANALYSIS OF IRONOUT HF RANDOMIZED CONTROLLED TRIAL.
- PO 376** HEART RATE CORRECTED PEAK O₂ PULSE AS A SIGNIFICANT PREDICTOR OF CARDIOVASCULAR ADVERSE EVENTS IN HEART FAILURE PATIENTS
- PO 377** INCIDENCE OF ATRIAL FIBRILLATION DURING THE FIRST WEEK OF BLANKING PERIOD: PULSED-FIELD ABLATION VS HIGH-POWER SHORT-DURATION RADIOFREQUENCY ABLATION
- PO 378** SURGICAL ABLATION OF ATRIAL FIBRILLATION CONCOMITANT WITH VALVULAR SURGERY: IS IT WORTHED?